<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02869009</url>
  </required_header>
  <id_info>
    <org_study_id>k2016-06</org_study_id>
    <nct_id>NCT02869009</nct_id>
  </id_info>
  <brief_title>Antiplatelet Therapy in Acute Mild-Moderate Ischemic Stroke</brief_title>
  <acronym>ATAMIS</acronym>
  <official_title>Antiplatelet Therapy in Acute Mild-Moderate Ischemic Stroke (ATAMIS): a Parallel Randomized, Open-label, Multicenter, Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>General Hospital of Shenyang Military Region</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>General Hospital of Shenyang Military Region</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The risk of early recurrence or progression of acute ischemic stroke is very high, even in
      patients treated with aspirin. The Chance study show that clopidogrel plus aspirin treatment
      reduced the risk of recurrent stroke in patients with transient ischemic attack (TIA) or
      minor ischemic stroke (NIHSS ≤ 3) within 24 hour onset and was not associated with increased
      hemorrhage events, compared with aspirin monotherapy. However, it is not known whether the
      dual antiplatelet treatment could reduce the risk of early recurrence or progression in
      patients with acute mild to moderate ischemic stroke (4 ≤ NIHSS ≤ 10). The investigators
      hypothesise that clopidogrel-aspirin treatment will be superior to aspirin monotherapy in
      this group of patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The ATAMIS study is a multicentre, prospective, randomised, open-label, controlled trial with
      a target enrollment of 3,000 patients from 60 centres of the Northeast China. Eligible
      patients are as follows: (1) definite acute ischemic stroke; (2) neurological deficit: 4 ≤
      NIHSS ≤ 10; (3) time from onset to drug treatment: within 48 hours.

      Patients in the clopidogrel-aspirin group will receive a 300mg loading dose of clopidogrel,
      followed by clopidogrel 75 mg/d and aspirin 75 mg/d from day 2 to day 14, and followed by
      clopidogrel 75 mg/d or aspirin 100 mg/d from day 15 to day 90.

      Patients in the aspirin-alone group will receive 100-300 mg aspirin from day 1 to day 14,
      followed by aspirin 100 mg/d from day 15 to day 90.

      The primary efficacy end point is early neurological deterioration assessed as a change of
      NIHSS: no change of NIHSS within 14 days.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Early neurological deterioration assessed as change of NIHSS</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>new clinical vascular events (ischemic stroke/hemorrhagic stroke/TIA/myocardial infarction/vascular death)</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in National Institute of Health stroke scale scores</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>moderate to severe bleeding events</measure>
    <time_frame>14 days</time_frame>
    <description>cerebral hemorrhage，hemorrhage of digestive tract, or moderate to severe bleeding of other organs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total mortality</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events/severe adverse events</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>clopidogrel plus aspirin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>the group will receive a 300mg loading dose of clopidogrel plus aspirin 100 mg, followed by clopidogrel 75 mg/d and aspirin 100 mg/d from day 2 to day 14, and followed by clopidogrel 75 mg/d or aspirin 100 mg/d from day 15 to day 90.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>aspirin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>the group will receive 100-300 mg aspirin from day 1 to day 14, followed by aspirin 100 mg/d from day 15 to day 90.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clopidogrel</intervention_name>
    <arm_group_label>clopidogrel plus aspirin group</arm_group_label>
    <other_name>Plavix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <arm_group_label>clopidogrel plus aspirin group</arm_group_label>
    <arm_group_label>aspirin group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Acute ischemic stroke that can be randomized within 48 hours of symptoms onset

          -  neurological deficit: 4 ≤ NIHSS ≤ 10

          -  CT or MRI scan ruling out hemorrhage or other pathology

          -  the first onset of ischemic stroke or previous stroke with no obvious sequelae (mRS≤1)

          -  Signed informed consent by patient self or legally authorized representatives

        Exclusion Criteria:

          -  intracranial hemorrhage and hemorrhagic cerebral infarction

          -  Thrombolysis for ischemic stroke

          -  Allergy to clopidogrel and/or aspirin

          -  History of stroke with serious sequelae

          -  Severe systemic disease (such as severe infection, severe hepatic and renal
             dysfunction)

          -  Clear indication for anticoagulation (atrial fibrillation, mechanical cardiac valves,
             deep venous thrombosis, pulmonary embolism)

          -  History of intracranial hemorrhage

          -  Planned treatment with nonsteroidal anti-inflammatory drugs to affect platelet
             function

          -  Anticoagulation within 10 days

          -  Gastrointestinal bleed or major surgery within 3 months

          -  Planned or likely revascularization (any angioplasty or vascular surgery) within the
             next 3 months

          -  Planned surgery or intervention to stop antiplatelet therapy

          -  Ischemic stroke induced by angiography or surgery

          -  Pregnancy or childbirth within the previous 4 weeks

          -  Patients who have been treated with any other investigational drug within 3 months of
             enrollment

          -  Severe noncardiovascular comorbidity with life expectancy &lt;3 months

          -  Any condition or situation which, in the opinion of the investigator, might pose a
             risk to the patient or confound the results of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hui-Sheng Chen</last_name>
    <role>Study Director</role>
    <affiliation>General Hospital of Shenyang Military Region</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xin-Hong Wang</last_name>
    <role>Principal Investigator</role>
    <affiliation>General Hospital of Shenyang Military Region</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hui-Sheng Chen</last_name>
    <phone>86-24-28897511</phone>
    <email>chszh@aliyun.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xin-Hong Wang</last_name>
    <phone>86-15309885658</phone>
    <email>450341972@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>General Hospital of Shenyang Military Region</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hui-Sheng Chen</last_name>
      <phone>86-24-28897511</phone>
      <email>chszh@aliyun.com</email>
    </contact>
    <contact_backup>
      <last_name>Xin-hong Wang</last_name>
      <phone>86-15309885658</phone>
      <email>450341972@qq.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Wang Y, Wang Y, Zhao X, Liu L, Wang D, Wang C, Wang C, Li H, Meng X, Cui L, Jia J, Dong Q, Xu A, Zeng J, Li Y, Wang Z, Xia H, Johnston SC; CHANCE Investigators. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med. 2013 Jul 4;369(1):11-9. doi: 10.1056/NEJMoa1215340. Epub 2013 Jun 26.</citation>
    <PMID>23803136</PMID>
  </reference>
  <reference>
    <citation>Wong KS, Chen C, Fu J, Chang HM, Suwanwela NC, Huang YN, Han Z, Tan KS, Ratanakorn D, Chollate P, Zhao Y, Koh A, Hao Q, Markus HS; CLAIR study investigators. Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a randomised, open-label, blinded-endpoint trial. Lancet Neurol. 2010 May;9(5):489-97. doi: 10.1016/S1474-4422(10)70060-0. Epub 2010 Mar 22.</citation>
    <PMID>20335070</PMID>
  </reference>
  <reference>
    <citation>Kennedy J, Hill MD, Ryckborst KJ, Eliasziw M, Demchuk AM, Buchan AM; FASTER Investigators. Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial. Lancet Neurol. 2007 Nov;6(11):961-9. Epub 2007 Oct 10.</citation>
    <PMID>17931979</PMID>
  </reference>
  <reference>
    <citation>Markus HS, Droste DW, Kaps M, Larrue V, Lees KR, Siebler M, Ringelstein EB. Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial. Circulation. 2005 May 3;111(17):2233-40. Epub 2005 Apr 25.</citation>
    <PMID>15851601</PMID>
  </reference>
  <reference>
    <citation>Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo L, Booth J, Topol EJ; CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006 Apr 20;354(16):1706-17. Epub 2006 Mar 12.</citation>
    <PMID>16531616</PMID>
  </reference>
  <reference>
    <citation>Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, Leys D, Matias-Guiu J, Rupprecht HJ; MATCH investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004 Jul 24-30;364(9431):331-7.</citation>
    <PMID>15276392</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 1, 2016</study_first_submitted>
  <study_first_submitted_qc>August 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2016</study_first_posted>
  <last_update_submitted>May 17, 2018</last_update_submitted>
  <last_update_submitted_qc>May 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>General Hospital of Shenyang Military Region</investigator_affiliation>
    <investigator_full_name>Hui-Sheng Chen</investigator_full_name>
    <investigator_title>Director of neurological department</investigator_title>
  </responsible_party>
  <keyword>stroke</keyword>
  <keyword>clopidogrel</keyword>
  <keyword>antiplatelets</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

